SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced the appointment of biotechnology and pharmaceutical
industry expert Alison A. Armour,
M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice
president, research and development, effective immediately. In this
role, she will report to Dr. Helen
Torley, president and chief executive officer.
Dr. Armour will lead Halozyme's research, clinical development,
regulatory, safety and pharmacovigilance efforts. Alison's
immediate focus will be the PEGPH20 regulatory submissions for
pancreas cancer in the event of positive data. She will also play a
key role in shaping the PEGPH20 new indication development strategy
and expanding our oncology portfolio.
"I am delighted to welcome Alison to Halozyme," said Dr. Torley.
"She brings a wealth of experience in all stages of oncology drug
development, as well as over 15 years of practice as a clinical
oncologist. Her experience and strong record of overseeing
successful regulatory submissions makes Alison a valuable addition
to our leadership team."
Dr. Armour joins Halozyme from Endocyte, where she served as
Chief Medical Officer and was responsible for the company's
clinical division, including all medical, clinical operations,
regulatory, data management and pharmacovigilance activities. In
this position, she worked on all aspects of the company's
portfolio, including folate and PSMA and CAR-T therapies. She
played a key role in Endocyte's successful in-licensing deal of
PSMA617 in 2017 and the subsequent development process that
resulted in Endocyte's sale to Novartis for $2.1 billion in December 2018.
Prior to joining Endocyte, Dr. Armour served as Vice President
of Development and team lead for TYKERB® at GSK and then
at Novartis. Earlier in her career, Dr. Armour also served as
global medical science director at AstraZeneca, where she led
early, late stage, and post-commercial medical development for
IRESSA®, obtaining the first EGFRm+ approval in
non-small cell lung cancer (NSCLS) for the drug.
"I am excited to join Halozyme and contribute to its efforts to
bring innovative new therapies to the market that can improve
patients' lives utilizing my experience in drug development and
oncology," said Dr. Armour.
Dr. Armour is known in the industry for her research and her
leadership in the areas of medical and radiation oncology—she has
co-authored two textbooks and more than 60 publications. Dr. Armour
earned her B.Sc. in Biochemistry, her M.B., Ch.B., M.Sc., and
Doctorate of Medicine from the University of
Glasgow; her FRCR at the Royal College of Radiologists
London, UK and her FRCP at the
Royal College of Physicians in London,
UK, for contributions to the field of oncology.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, potential expansion of the Company's oncology portfolio
and statements concerning the possible activity, benefits and
attributes of PEGPH20, the possible method of action of PEGPH20,
its potential application to improve cancer therapies and
statements concerning future actions relating to the development of
PEGPH20, including potential regulatory submissions and
potential new PEGPH20 indications) that involve risk and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected results or delays in development and regulatory review
of PEGPH20, regulatory approval requirements, unexpected adverse
events and competitive conditions. These and other factors that may
result in differences are discussed in greater detail in the
Company's most recent Annual and Quarterly Reports filed with the
Securities and Exchange Commission.
Halozyme contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-names-dr-alison-a-armour-as-senior-vice-president-of-research-and-development-300843858.html
SOURCE Halozyme Therapeutics, Inc.